Aktiesnakken — November 2009
-
de er MEGET syge...og derfor også fast track, så der er det bedre at gå i 1st line
-
bivirkningsprofilen for Arzerra er gennemgående bedre end for Rituxian
-
morgenpliiing
-
credit suisse kursmål 57 på genmab
-
yep men godt med en tråd om det
-
det virker da en smule grotesk
-
gad godt se den analyse og det regneark
-
hvis de har peak sales 435 mill så regner de ikke engang med cll!
-
madsK det er nok mere pepaoter du skal tale om
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind